Search

Clonal gene therapy protocols based on the precise manipulation of epidermal stem cells require highly efficient gene-editing molecular tools. We have combined adeno-associated virus (AAV)-mediated delivery of donor template DNA with transcription activator-like nucleases (TALE) expressed by adenoviral vectors to address the correction of the c.6527insC mutation in the COL7A1 gene, causing recessive dystrophic epidermolysis bullosa in a high percentage of Spanish patients. After transduction with these viral vectors, high frequencies of homology-directed repair were found in clones of keratinocytes derived from a recessive dystrophic epidermolysis bullosa (RDEB) patient homozygous for the c.6527insC mutation. Gene-edited clones recovered the expression of the COL7A1 transcript and collagen VII protein at physiological levels. In addition, treatment of patient keratinocytes with TALE nucleases in the absence of a donor template DNA resulted in nonhomologous end joining (NHEJ)-mediated indel generation in the vicinity of the c.6527insC mutation site in a large proportion of keratinocyte clones. A subset of these indels restored the reading frame of COL7A1 and resulted in abundant, supraphysiological expression levels of mutant or truncated collagen VII protein. Keratinocyte clones corrected both by homology-directed repair (HDR) or NHEJ were used to regenerate skin displaying collagen VII in the dermo-epidermal junction.

The management of network resources, defined as one owned by the partners of a business or that accesses through their relationships, is a general question in the development of alliances and agreements. The type of network resources that will be necessary for the company may be affected by the time of its life cycle and by if the company has an attitude of exploration or exploitation in the design and management of cooperative strategies. We propose a new framework of the life cycle as a continuum between young and established companies. This paper analyzes these relations in the airline industry globally. The results show the consolidated companies continue simultaneously conduct exploration and exploitation and that when they seek resources latter basically these are linked to knowledge and technology., La gestión de los recursos de red, entendidos como aquellos que son propiedad de los socios de una empresa y a los que accede a través de sus relaciones, es una cuestión básica en el desarrollo de alianzas y acuerdos. El tipo de recursos de red que serán necesarios para la empresa puede estar condicionado por el momento del ciclo de vida en que se encuentre y de si tiene una actitud de exploración o de explotación en el diseño y gestión de sus estrategias de cooperación. Se plantea una nueva consideración del ciclo de vida como un continuo entre empresas jóvenes y empresas consolidadas. Este trabajo analiza estas relaciones en el sector de las aerolíneas a nivel global. Los resultados muestran que las empresas consolidadas siguen simultáneamente un comportamiento de exploración y de explotación y que cuando se dan estos últimos se buscan recursos básicamente ligados al conocimiento y a la tecnología.

T cells recognize antigens via their cell surface TCR and are classified as either αβ or γδ depending on the variable chains in their TCR, α and β or γ and δ, respectively. Both αβ and γδ TCRs also contain several invariant chains, including CD3δ, which support surface TCR expression and transduce the TCR signal. Mutations in variable chains would be expected to affect a single T cell lineage, while mutations in the invariant chains would affect all T cells. Consistent with this, all CD3δ-deficient patients described to date showed a complete block in T cell development. However, CD3δ-KO mice have an αβ T cell-specific defect. Here, we report 2 unrelated cases of SCID with a selective block in αβ but not in γδ T cell development, associated with a new splicing mutation in the CD3D gene. The patients' T cells showed reduced CD3D transcripts, CD3δ proteins, surface TCR, and early TCR signaling. Their lymph nodes showed severe T cell depletion, recent thymus emigrants in peripheral blood were strongly decreased, and the scant αβ T cells were oligoclonal. T cell-dependent B cell functions were also impaired, despite the presence of normal B cell numbers. Strikingly, despite the specific loss of αβ T cells, surface TCR expression was more reduced in γδ than in αβ T cells. Analysis of individuals with this CD3D mutation thus demonstrates the contrasting CD3δ requirements for αβ versus γδ T cell development and TCR expression in humans and highlights the diagnostic and clinical relevance of studying both TCR isotypes when a T cell defect is suspected.

Many studies have examined the relations between individuals and organizations and their influence on innovativeness. Some have looked at networks that improve innovative activity at an organizational, departmental and individual level, using in the latter case the individual's egonet. This study explores the way in which an individual's social capital and each of its three dimensions affect innovativeness. Having assessed the entire network of a university department and calculated the social capital of its members, their innovativeness was compared on the basis of their scientific production. The results show that the positions of researchers in the network structure and network quality are less important than the resources that they are able to access through their relations.

Here we report the functional assessment of two novel deafness-associated gamma-actin mutants, K118N and E241K, in a spectrum of different situations with increasing biological complexity by combining biochemical and cell biological analysis in yeast and mammalian cells. Our in vivo experiments showed that while the K118N had a very mild effect on yeast behaviour, the phenotype caused by the E241K mutation was very severe and characterized by a highly compromised ability to grow on glycerol as a carbon source, an aberrant multi-vacuolar pattern and the deposition of thick F-actin bundles randomly in the cell. The latter feature is consistent with the highly unusual spontaneous tendency of the E241K mutant to form bundles in vitro, although this propensity to bundle was neutralized by tropomyosin and the E241K filament bundles were hypersensitive to severing in the presence of cofilin. In transiently transfected NIH3T3 cells both mutant actins were normally incorporated into cytoskeleton structures, although cytoplasmic aggregates were also observed indicating an element of abnormality caused by the mutations in vivo. Interestingly, gene-gun mediated expression of these mutants in cochlear hair cells results in no gross alteration in cytoskeletal structures or the morphology of stereocilia. Our results provide a more complete picture of the biological consequences of deafness-associated gamma-actin mutants and support the hypothesis that the post-lingual and progressive nature of the DFNA20/26 hearing loss is the result of a progressive deterioration of the hair cell cytoskeleton over time.

Miguel Moreno-Pelayo and colleagues report mutations in the seed region of human miR-96 segregating with progressive hearing loss in two families. In an accompanying paper, Karen Steel and colleagues show that the mouse diminuendo mutant, which also shows progressive hearing loss, carries a similar mutation in the seed region of mouse miR-96. MicroRNAs (miRNAs) bind to complementary sites in their target mRNAs to mediate post-transcriptional repression1,2, with the specificity of target recognition being crucially dependent on the miRNA seed region3. Impaired miRNA target binding resulting from SNPs within mRNA target sites has been shown to lead to pathologies associated with dysregulated gene expression4,5,6,7. However, no pathogenic mutations within the mature sequence of a miRNA have been reported so far. Here we show that point mutations in the seed region of miR-96, a miRNA expressed in hair cells of the inner ear8, result in autosomal dominant, progressive hearing loss. This is the first study implicating a miRNA in a mendelian disorder. The identified mutations have a strong impact on miR-96 biogenesis and result in a significant reduction of mRNA targeting. We propose that these mutations alter the regulatory role of miR-96 in maintaining gene expression profiles in hair cells required for their normal function.

The TECTA gene encodes alpha-tectorin (TECTA), a major noncollagenous component of the tectorial membrane (TM). In humans, mutations in TECTA lead to either dominant (DFNA8/A12) or recessive (DFNB21) forms of nonsyndromic hearing loss. All missense mutations in TECTA that have been reported thus far are associated with the dominant subtype, whereas those leading to recessive deafness are all inactivating mutations. In this paper, we characterize a spontaneous missense mutation (c.1046C > A, p.A349D) arising in the mouse Tecta gene that is, unlike all previously reported missense mutations in TECTA, recessive. The morphological phenotype of the TectaA349D/A349D mouse resembles but is not identical to that previously described for the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$Tecta^{{{\Delta {\text{ENT}}} \mathord{\left/ {\vphantom {{\Delta {\text{ENT}}} {\Delta {\text{ENT}}}}} \right. \kern-\nulldelimiterspace} {\Delta {\text{ENT}}}}} $$\end{document} mouse. As in the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$Tecta^{{{\Delta {\text{ENT}}} \mathord{\left/ {\vphantom {{\Delta {\text{ENT}}} {\Delta {\text{ENT}}}}} \right. \kern-\nulldelimiterspace} {\Delta {\text{ENT}}}}} $$\end{document} mouse, the TM is completely detached from the surface of the organ of Corti and spiral limbus, lacks a striated-sheet matrix, and is deficient in both beta-tectorin (Tectb) and otogelin. A significant amount of Tecta is, however, detected in the TM of the TectaA349D/A349D mouse, and numerous, electron-dense matrix granules are seen interspersed among the disorganized collagen fibrils. Mutated TectaA349D is therefore incorporated into the TM but presumably unable to interact with either Tectb or otogelin. The TectaA349D/A349D mouse reveals that missense mutations in Tecta can be recessive and lead to TM detachment and suggests that should similar mutations arise in the human population, they would likely cause deafness.

Mutations in the potassium channel gene KCNQ4 underlie DFNA2, a subtype of autosomal dominant progressive, high-frequency hearing loss. Based on a phenotype-guided mutational screening we have identified a novel mutation c.886G>A, leading to the p.G296S substitution in the pore region of KCNQ4 channel. The possible impact of this mutation on total KCNQ4 protein expression, relative surface expression and channel function was investigated. When the G296S mutant was expressed in Xenopus oocytes, electrophysiological recordings did not show voltage-activated K+ currents. The p.G296S mutation impaired KCNQ4 channel activity in two manners. It greatly reduced surface expression and, secondarily, abolished channel function. The deficient expression at the cell surface membrane was further confirmed in non-permeabilized NIH-3T3 cells transfected with the mutant KCNQ4 tagged with the hemagglutinin epitope in the extracellular S1-S2 linker. Co-expression of mutant and wild type KCNQ4 in oocytes was performed to mimic the heterozygous condition of the p.G296S mutation in the patients. The results showed that the G296S mutant exerts a strong dominant-negative effect on potassium currents by reducing the wild type KCNQ4 channel expression at the cell surface. This is the first study to identify a trafficking-dependent dominant mechanism for the loss of KCNQ4 channel function in DFNA2. © Springer-Verlag 2007.

The biological role in vivo of the homologous CD3 gamma and delta invariant chains within the human TCR/CD3 complex is a matter of debate, as murine models do not recapitulate human immunodeficiencies. We have characterized, in a Turkish family, two new patients with complete CD3 gamma deficiency and SCID symptoms and compared them with three CD3 gamma-deficient individuals belonging to two families from Turkey and Spain. All tested patients shared similar immunological features such as a partial TCR/CD3 expression defect, mild alpha beta and gamma delta T lymphocytopenia, poor in vitro proliferative responses to Ags and mitogens at diagnosis, and very low TCR rearrangement excision circles and CD45RA(+) alpha beta T cells. However, intrafamilial and interfamilial clinical variability was observed in patients carrying the same CD3G mutations. Two reached the second or third decade in healthy conditions, whereas the other three showed lethal SCID features with enteropathy early in life. In contrast, all reported human complete CD3 delta (or CD3 epsilon) deficiencies are in infants with life-threatening SCID and very severe alpha beta and gamma delta T lymphocytopenia. Thus, the peripheral T lymphocyte pool was comparatively well preserved in human CD3 gamma deficiencies despite poor thymus output or clinical outcome. We propose. a CD3 gamma >> CD3 gamma hierarchy for the relative impact of their absence on the signaling for T cell production in humans.

Epidermolysis bullosa with pyloric atresia (EB-PA) is a rare autosomal recessive hereditary disease with a variable prognosis from lethal to very mild. EB-PA is classified into Simplex form (EBS-PA: OMIM #612138) and Junctional form (JEB-PA: OMIM #226730), and it is caused by mutations in ITGA6, ITGB4 and PLEC genes. We report the analysis of six patients with EB-PA, including two dizygotic twins. Skin immunofluorescence epitope mapping was performed followed by PCR and direct sequencing of the ITGB4 gene. Two of the patients presented with non-lethal EB-PA associated with missense ITGB4 gene mutations. For the other four, early postnatal demise was associated with complete lack of β4 integrin due to a variety of ITGB4 novel mutations (2 large deletions, 1 splice-site mutation and 3 missense mutations). One of the deletions spanned 278 bp, being one of the largest reported to date for this gene. Remarkably, we also found for the first time a founder effect for one novel mutation in the ITGB4 gene. We have identified 6 novel mutations in the ITGB4 gene to be added to the mutation database. Our results reveal genotype-phenotype correlations that contribute to the molecular understanding of this heterogeneous disease, a pivotal issue for prognosis and for the development of novel evidence-based therapeutic options for EB management.

Los complementos alimenticios son alimentos cuyo fin es complementar la dieta normal y que consisten en fuentes concentradas de nutrientes (vitaminas y minerales) o de otras sustancias que tienen un efecto nutricional o fisiológico, en forma simple o combinada. Los complementos se comercializan en forma dosificada, se entregan al consumidor final únicamente preenvasados. En ningún caso, deben sustituir al uso de medicamentos sin una supervisión médica adecuada. Sólo deben utilizarse para complementar la dieta y, de forma general, su uso no es necesario si se sigue una dieta variada y equilibrada, a la que no pueden reemplazar. En España los complementos alimenticios están regulados por el Real Decreto 1487/2009 que traspuso a la legislación española la Directiva 2002/46/CE relativa a la aproximación de las legislaciones de los estados miembros en materia de complementos alimenticios. Sin embargo, actualmente sólo está regulado el uso de vitaminas y minerales, por lo que se ha solicitado al Comité Científico que realice una valoración de la propuesta de autorización de la utilización de determinadas sustancias distintas de vitaminas y minerales en la fabricación de complementos alimenticios. Las sustancias propuestas por la Agencia Española de Consumo, Seguridad Alimentaria y Nutrición (AECOSAN) son: ácido L-aspártico, L-citrulina, glicina, L-prolina, L-serina, L-arginina-L-aspartato, L-lisina-L-aspartato, L-lisina-L-glutamato, N-acetil-L-cisteína, N-acetil-L-metionina, hidroximetilbu- tirato, ácido lipoico, Monascus purpureus, carbón activo y lactulosa. El Comité Científico ha valorado cada propuesta, analizando las características y fuentes de cada sustancia, así como la nutrición, metabolismo y seguridad y ha concluido, en cada caso, si la presentada por la AECOSAN era aceptable desde el punto de vista de su seguridad en su uso como complemento alimenticio. En ningún caso, la evaluación realizada supone un aval de la eficacia biológica de las sustancias y dosis valoradas. El Comité Científico indica que, en todo caso es necesario que las personas que estén sometidas a tratamientos con medicamentos consulten con su médico la oportunidad o conveniencia de consumir complementos alimenticios dada la posibilidad de que existan interferencias en algunos casos. Food supplements are foods, the purpose of which is to supplement the normal diet and which consist of concentrated nutrient sources (vitamins and minerals) or other substances with a nutritional or physiological effect, alone or in combination. The supplements are marketed in dosage form and are only supplied to the end consumer prepacked. In no event should they replace the use of medicines without suitable medical supervision. They should only be used to supplement the diet and, on the whole, their usage is not required if the individual has a varied and balanced diet, which cannot be replaced. In Spain, food supplements are regulated by Royal Decree 1487/2009, which transposed Directive 2002/46/EC on the approximation of the laws of the Member States relating to food supplements into Spanish law. However, only the use of vitamins and minerals is currently regulated. Therefore the Scientific Committee has been asked to make an assessment of the proposal to authorise certain substances other than vitamins and minerals in the manufacture of food supplements. The substances proposed by the Spanish Agency for Consumer Affairs, Food Safety and Nutrition (AECOSAN) are food supplements, L-aspartic acid, L-citrulline, glycine, L-proline, L-serine, L-arginine-L-aspar- tate, L-lysine L-aspartate, L-lysine-L-glutamate, N-acetyl-L-cysteine, N-acetyl-L-methionine, hidro- xymethylbutyrate, lipoic acid, Monascus purpureus, activated carbon and lactulose. The Scientific Committee has assessed each proposal, analysing the characteristics and sources of each substance, and the nutrition, metabolism and safety and has concluded, in each case, whether that submitted by the AECOSAN is acceptable from a safety viewpoint for use as a food supplement. In no event is the assessment intended as a guarantee of the biological efficiency of the substances and doses assessed. The Scientific Committee states that, in any case individuals undergoing medical treatment must seek medical advice as to the suitability of taking food supplements, given the possibility of interactions in certain cases.

Tribulus terrestris L. es una planta de la familia Zygophyllaceae cuyo uso en complementos alimenticios está autorizado en varios países de la Unión Europea y que contiene de manera natural varias sustancias activas, entre las que destacan saponósidos esteroídicos, alcaloides b-carbolínicos, favonoides y lignanamidas. La toxicidad de Tribulus terrestris en animales ha sido ampliamente documentada a lo largo de su historia como planta medicinal y se describen efectos negativos a nivel neuronal, muscular, hepático y renal. Algunos países consideran que utilizar partes de la planta de Tribulus terrestris en la elaboración de complementos alimenticios no es seguro, por lo que impiden su comercialización y lo comunican al sistema de alertas europeo RASFF (Rapid Alert System for Food and Feed). El Comité Científico ha realizado una evaluación del riesgo a fin de determinar si el consumo de frutos, partes aéreas de la planta y sus extractos de Tribulus terrestris en complementos alimenticios es seguro y ha concluido que no hay disponibles datos toxicológicos suficientes que permitan evaluar la seguridad del uso de partes de la planta de Tribulus terrestris en complementos alimenticios. En cualquier caso, se considera que las cantidades máximas diarias de Tribulus terrestris en complementos alimenticios no deberían superar las dosis de uso farmacológico y que en los complementos debería constar la parte de la planta empleada, y si se trata de un extracto u otra forma de preparación, así como el contenido en saponósidos. Tribulus terrestris L. is a plant from the Zygophyllaceae family whose use in food supplements is authorised in various European Union countries. In its natural form, it contains various active substances, the most notable of which are steroidal saponins, b-Carboline alkaloids, flavonoids and lignanamides. Tribulus terrestris’ toxicity to animals has been widely documented throughout its history as a medicinal plant and it has been reported to have negative neuronal, muscular, hepatic and renal effects. Some countries consider using parts of the Tribulus terrestris plant to produce food supplements to be unsafe so they do not allow such supplements to be sold. This is reported through the European Rapid Alert System for Food and Feed (RASFF). The Scientific Committee has conducted a risk assessment with the aim of determining whether consuming fruit, plant shoots and their extracts from Tribulus terrestris in food supplements is safe, concluding that there is insufficient toxicological data to assess how safe using parts of the Tribulus terrestris plant in food supplements is. In any case, the maximum daily quantity of Tribulus terrestris in food supplements should not exceed the dose used for pharmacological purposes and the part of the plant used, whether it was extracted or prepared in some other way and its saponin content should all be made clear on the supplement itself.

Alliance Portfolio Configuration (APC) conditions access to network resources, however, not all access to partner resources is finally mobilized by the firm. Our paper contributes to the understanding of alliance portfolio performance by examining how an acceptable configuration of the alliance portfolio will be conditioned by the level of resource mobilization that the firm really achieves. A variance-based structural equation modelling (Partial Least Squares) has been applied to a sample from the Top International Airlines database. Results from the data analysis show that the Level of Network Resource Mobilization (LNRM) (a) fully mediate the effect of alliance portfolio configuration on the operating performance; and (b) partially mediate this effect on financial performance of airlines.

Los complementos alimenticios son alimentos cuyo fin es complementar la dieta normal y que consisten en fuentes concentradas de nutrientes (vitaminas y minerales) o de otras sustancias que tienen un efecto nutricional o fisiológico, en forma simple o combinada. Los complementos se comercializan en forma dosificada, se entregan al consumidor final únicamente preenvasados. En ningún caso, deben sustituir al uso de medicamentos sin una supervisión médica adecuada. Sólo deben utilizarse para complementar la dieta y, de forma general, su uso no es necesario si se sigue una dieta variada y equilibrada, a la que no pueden reemplazar. En España los complementos alimenticios están regulados por el Real Decreto 1487/2009 que traspuso a la legislación española la Directiva 2002/46/CE relativa a la aproximación de las legislaciones de los estados miembros en materia de complementos alimenticios. Sin embargo, actualmente sólo está regulado el uso de vitaminas y minerales, por lo que se ha solicitado al Comité Científico que realice una valoración de la propuesta de autorización de la utilización de determinadas sustancias distintas de vitaminas y minerales en la fabricación de complementos alimenticios. Las sustancias propuestas por la Agencia Española de Consumo, Seguridad Alimentaria y Nutrición (AECOSAN) son: ácido L-aspártico, L-citrulina, glicina, L-prolina, L-serina, L-arginina-L-aspartato, L-lisina-L-aspartato, L-lisina-L-glutamato, N-acetil-L-cisteína, N-acetil-L-metionina, hidroximetilbu- tirato, ácido lipoico, Monascus purpureus, carbón activo y lactulosa. El Comité Científico ha valorado cada propuesta, analizando las características y fuentes de cada sustancia, así como la nutrición, metabolismo y seguridad y ha concluido, en cada caso, si la presentada por la AECOSAN era aceptable desde el punto de vista de su seguridad en su uso como complemento alimenticio. En ningún caso, la evaluación realizada supone un aval de la eficacia biológica de las sustancias y dosis valoradas. El Comité Científico indica que, en todo caso es necesario que las personas que estén sometidas a tratamientos con medicamentos consulten con su médico la oportunidad o conveniencia de consumir complementos alimenticios dada la posibilidad de que existan interferencias en algunos casos. Food supplements are foods, the purpose of which is to supplement the normal diet and which consist of concentrated nutrient sources (vitamins and minerals) or other substances with a nutritional or physiological effect, alone or in combination. The supplements are marketed in dosage form and are only supplied to the end consumer prepacked. In no event should they replace the use of medicines without suitable medical supervision. They should only be used to supplement the diet and, on the whole, their usage is not required if the individual has a varied and balanced diet, which cannot be replaced. In Spain, food supplements are regulated by Royal Decree 1487/2009, which transposed Directive 2002/46/EC on the approximation of the laws of the Member States relating to food supplements into Spanish law. However, only the use of vitamins and minerals is currently regulated. Therefore the Scientific Committee has been asked to make an assessment of the proposal to authorise certain substances other than vitamins and minerals in the manufacture of food supplements. The substances proposed by the Spanish Agency for Consumer Affairs, Food Safety and Nutrition (AECOSAN) are food supplements, L-aspartic acid, L-citrulline, glycine, L-proline, L-serine, L-arginine-L-aspar- tate, L-lysine L-aspartate, L-lysine-L-glutamate, N-acetyl-L-cysteine, N-acetyl-L-methionine, hidro- xymethylbutyrate, lipoic acid, Monascus purpureus, activated carbon and lactulose. The Scientific Committee has assessed each proposal, analysing the characteristics and sources of each substance, and the nutrition, metabolism and safety and has concluded, in each case, whether that submitted by the AECOSAN is acceptable from a safety viewpoint for use as a food supplement. In no event is the assessment intended as a guarantee of the biological efficiency of the substances and doses assessed. The Scientific Committee states that, in any case individuals undergoing medical treatment must seek medical advice as to the suitability of taking food supplements, given the possibility of interactions in certain cases.

T lymphocytes play a crucial role in the pathogenesis of inflammatory bowel disease. Achieving stable T-cell lines, rather than continuous bleeding of patients, is desirable in order to dissect their implication in the disease.Long-lasting T-cell lines from patients with Crohn disease and ulcerative colitis and from healthy volunteers have been obtained by transformation of T lymphocytes using the lymphotropic Herpesvirus saimiri. Lines were subjected to phenotypic and functional analyses, and the results compared with freshly isolated peripheral blood mononuclear cells.Fresh cells revealed only minor differences between patients and controls, with regard to phenotype and proliferative capacity. In contrast, the use of T-cell lines showed that cells from Crohn disease patients, but not ulcerative colitis patients, over-responded to several membrane or cytoplasmic stimuli when compared to control T-cell lines. Thus, higher responses were found when stimulated with alphaCD3 and IL2, alphaCD3 and alphaCD28, IL2 alone, phorbol esters (PMA) and alphaCD3 and, finally, PMA and alphaCD2 (P0.05 in all instances). Further, lines from patients with Crohn disease responded more vigorously to alphaCD3 and alphaCD28 or alphaCD3 and PMA when compared to ulcerative colitis (P0.05 in both instances).The data obtained with these lines suggest that T cells from patients with Crohn disease differ in vivo in their proliferative capacity, as compared with those from ulcerative colitis patients, a finding that may reflect the clear Th-1 phenotype found in the former and absent in the latter.

Hereditary non-syndromic sensorineural hearing loss (NSSHL) is a genetically highly heterogeneous group of disorders. Autosomal dominant forms account for up to 20% of cases. To date, 39 loci have been identified by linkage analysis of affected families that segregate NSSHL forms in the autosomal dominant mode (DFNA). Investigation of a large Spanish pedigree with autosomal dominant inheritance of bilateral and progressive NSSHL of postlingual onset excluded linkage to known DFNA loci and, in a subsequent genome-wide scan, the disorder locus was mapped to 3q28-29. A maximum two-point LOD score of 4.36 at theta=0 was obtained for marker D3S1601. Haplotype analysis placed the novel locus, DFNA44, within a 3-cM genetic interval defined by markers D3S1314 and D3S2418. Heteroduplex analysis and DNA sequencing of coding regions and exon/intron boundaries of two genes (CLDN16 and FGF12) in this interval did not reveal disease-causing mutations.

To dissect the phenotypic and functional features of mucosal T lymphocytes in patients with gastric adenocarcinoma, we have used the Herpesvirus saimiri transformation procedure to achieve T-cell lines from gastric origin. Once achieved, cell function was assessed by in vitro stimulation with mitogens. CD2-specific monoclonal antibodies (alpha-CD2), alone or in combination with interleukin (IL)-2, rendered fewer counts in patients (34 408+/-3965 and 52 157+/-6473 c.p.m., respectively) than in controls (67 471+/-11 755 c.p.m., P

et al., Recessive dystrophic epidermolysis bullosa (RDEB) is caused by deficiency of type VII collagen due to COL7A1 mutations such as c.6527insC, recurrently found in the Spanish RDEB population. Assessment of clonal correction-based therapeutic approaches for RDEB requires large expansions of cells, exceeding the replication capacity of human primary keratinocytes. Thus, immortalized RDEB cells with enhanced proliferative abilities would be valuable. Using either the SV40 large T antigen or papillomavirus HPV16-derived E6-E7 proteins, we immortalized and cloned RDEB keratinocytes carrying the c.6527insC mutation. Clones exhibited high proliferative and colony-forming features. Cytogenetic analysis revealed important differences between T antigen-driven and E6-E7-driven immortalization. Immortalized cells responded to differentiation stimuli and were competent for epidermal regeneration and recapitulation of the blistering RDEB phenotype in vivo. These features make these cell lines useful to test novel therapeutic approaches including those aimed at editing mutant COL7A1., FL was supported by grants from Instituto de Salud Carlos III (PI11/01225) and Comunidad de Madrid (S2010/BMD- 2359; SKINMODEL). MDR was supported by grants from the Science and Innovation Ministry of Spain (SAF2010-16976) and Comunidad de Madrid (S2010/BMD-2420; CELLCAM). MG is supported in part by ERA-NET grant: E-Rare-2 (SpliceEB).

Ejemplar dedicado a: Monográfico sobre Seguridad Alimentaria Las ventajas tecnológicas de la incorporación de arcillas modificadas en polímeros para el envasado de alimentos son bien conocidas, pero aún quedan muchas incertidumbres sobre la seguridad de estos materiales. El Instituto Tecnológico del Embalaje, Transporte y Logística ha desarrollado una arcilla, Clay1, modificando una montmorillonita con una sal de amonio cuaternario. Esta organoarcilla, incorporada al polímero (ácido poliláctico), da lugar a un material nanocompuesto, reforzándose así el material de partida. El principal objetivo de este estudio es evaluar la actividad de biomarcadores de estrés oxidativo en bazo de ratas expuestas durante 90 días a Clay1 (40 mg/kg/día) y al extracto de migración obtenido a partir del material nanocompuesto resultante. Los parámetros evaluados fueron la peroxidación lipídica y las actividades enzimáticas superóxido dismutasa y catalasa. Además, se realizó un análisis del contenido en bazo de los metales más característicos que componen la organoarcilla (Al, Ca, Fe, Mg, Si) para comprobar su posible acumulación. En dicho estudio se trabajó con tres grupos de ratas Wistar (n=10): control (comida estándar + agua como bebida), Clay1 (comida estándar mezclada con 40mg/kg/día de arcilla + agua) y extracto de Clay1 (comida estándar + extracto como bebida). Tras el tiempo de exposición los animales se sacrificaron y se extrajo el bazo. De forma general, no se observaron diferencias significativas en ninguno de los parámetros evaluados con respecto al grupo control, por lo que Clay1 muestra un buen perfil toxicológico respecto a los biomarcadores ensayados con vistas a su uso en la industria alimentaria. The technological advantages of the incorporation of modified clays into polymers for food packaging are well known. However, there are still many uncertainties about the safety of these materials. The Technological Institute of Packaging, Transport and Logistic has developed Clay1, a modified clay with a quaternary ammonium salt. This organoclay is incorporated into the polymer (polylactic acid), giving a nanocomposite material and reinforcing the bulk material. The aim of this study is to evaluate the activity of several oxidative stress biomarkers in the spleen of rats exposed for 90 days to Clay1 (40 mg/kg/day) and its migration extract obtained from the resultant nanocomposite material. The parameters evaluated were lipid peroxidation and superoxide dismutase and catalase activities. Moreover, the characteristic metallic components of the organoclay (Al, Ca, Fe, Mg, Si) were also analyzed to test the possible accumulation. In this study, three groups of Wistar rats (n=10) were used: control (standard food + water), Clay1 (food with Clay1+water) and Clay1 extract (standard food+ Clay1 extract as water). After the exposure the spleen was removed. In general, no significant differences were observed in any of the parameters evaluated compared to the control group, therefore Clay1 showed a good toxicologic profile regarding the biomarkers assayed for its use in the food industry. Ministerio de Ciencia e Innovación (España) AGL2010-21210 Junta de Andalucía (España) AGR5969

Junta de Andalucía AGR5969 Ministerio de Ciencia e Innovación AGL2010-21210

Ministerio de Ciencia e Innovación AGL2012-38357-C02-01 Junta de Andalucía AGR-7252

Junta de Andalucía AGR5969 Ministerio de Ciencia e Innovación (España) AGL2010-21210

Junta de Andalucía AGR5969 Ministerio de Ciencia e Innovación AGL2010-21210

Junta de Andalucía AGR5969 Ministerio de Ciencia e Innovación AGL2010-21210

La presente invención se refiere al uso de una composición que comprende N-acetilcisteína (NAC) para el tratamiento, prevención y/o recuperación de efectos tóxicos en peces expuestos a Microcistinas (MCs). También se refiere al uso de la citada composición en la recuperación de las alteraciones histopatológicas producidas en los tejidos de la lista que comprende hígado, riñón, corazón, branquias y/o tracto gastrointestinal. Además, dicha composición se utiliza para la fabricación de un alimento funcional, un complemento vitamínico, o un complemento nutricional

Ministerio de Ciencia e Innovación AGL2012-38357-C02-01 Junta de Andalucía AGR-7252

Junta de Andalucía AGR5969 Ministerio de Ciencia e Innovación AGL2010-21210

El aceite esencial de los componentes del género Allium, principalmente ajo y cebolla, presenta propiedades antioxidantes y antibacterianas debidas a la presencia de compuestos azufrados en su composición. La industria alimentaria ha comenzado a desarrollar nuevos sistemas de envasado activo a partir de polímeros seleccionados, a los que se incorporan aceites esenciales que, por sus propiedades, contribuyen a aumentar la vida útil de los alimentos perecederos. En este sentido, se hace necesario evaluar la seguridad asociada al uso de estas sustancias en envases alimentarios que van a estar en contacto con el consumidor a través del alimento. El objetivo del presente estudio fue determinar la citotoxicidad producida por dipropil sulfuro y dipropil disulfuro, dos de los componentes del aceite esencial de ajo y cebolla, en la línea celular Caco-2, células humanas procedentes de carcinoma de colon. Los biomarcadores ensayados fueron el contenido total de proteínas, la captación de rojo neutro y la reducción de la sal de tetrazolio (3-(4,5-dimetiltiazol-2- il)-5-(3-carboximetoxifenil)-2-(4sulfofenil)-2H-tetrazolio). Las células fueron expuestas durante 2, 4 y 8 h a concentraciones comprendidas entre 0 y 200 μM. Los resultados no mostraron diferencias significativas frente al control para ninguno de los tres marcadores, lo que demuestra que bajo las condiciones de los ensayos ambos compuestos azufrados no son citotóxicos para esta línea celular gastrointestinal y podrían ser útiles en la industria alimentaria para desarrollar envases activos. Allium spp. essential oil, mainly from garlic and onion, possesses different beneficial properties, for example antioxidant and antimicrobial effects, due to the presence of sulfur compounds. Food industry is developing new active packaging systems that include the essential oil of garlic in their structure, in order to improve the shelf-life of perishable products. Therefore it is necessary to evaluate the safety associated with the use of these substances in food packaging that will be in contact with the consumer through food. The aim of our study was to evaluate in vitro the cytotoxicity of dipropyl sulfide and dipropyl disulfide. For this purpose, we used the human Caco-2 cell line, from human small intestinal mucosa carcinoma. The assayed cytotoxicity biomarkers were the total protein content, neutral red uptake and reduction of the 3-( 4, 5 - dimethylthiazol - 2 - y l ) - 5 - ( 3 - carboximethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt. Cells were exposed to dipropyl sulfide and dipropyl disulfide in concentrations between 0-200 μM for 2, 4 and 8 h. After periods of exposure, no alterations were observed in any of the biomarkers assayed. These results suggest that both organosulfur compounds are safety options for food industry and could be a choice in the development of active packaging. Ministerio de Ciencia e Innovación (España) AGL2012-38357-C02-01 Junta de Andalucía AGR-7252 Servicio de Biología del Centro de Investigación, Tecnología e Innovación de la Universidad de Sevilla (CITIUS)

Ministerio de Educación y Ciencias AGL2009-10026 Junta de Andalucía AGR-04672

Item does not contain fulltext The prevalence of DFNA8/DFNA12 (DFNA8/12), a type of autosomal dominant nonsyndromic hearing loss (ADNSHL), is unknown as comprehensive population-based genetic screening has not been conducted. We therefore completed unbiased screening for TECTA mutations in a Spanish cohort of 372 probands from ADNSHL families. Three additional families (Spanish, Belgian, and English) known to be linked to DFNA8/12 were also included in the screening. In an additional cohort of 835 American ADNSHL families, we preselected 73 probands for TECTA screening based on audiometric data. In aggregate, we identified 23 TECTA mutations in this process. Remarkably, 20 of these mutations are novel, more than doubling the number of reported TECTA ADNSHL mutations from 13 to 33. Mutations lie in all domains of the alpha-tectorin protein, including those for the first time identified in the entactin domain, as well as the vWFD1, vWFD2, and vWFD3 repeats, and the D1-D2 and TIL2 connectors. Although the majority are private mutations, four of them-p.Cys1036Tyr, p.Cys1837Gly, p.Thr1866Met, and p.Arg1890Cys-were observed in more than one unrelated family. For two of these mutations founder effects were also confirmed. Our data validate previously observed genotype-phenotype correlations in DFNA8/12 and introduce new correlations. Specifically, mutations in the N-terminal region of alpha-tectorin (entactin domain, vWFD1, and vWFD2) lead to mid-frequency NSHL, a phenotype previously associated only with mutations in the ZP domain. Collectively, our results indicate that DFNA8/12 hearing loss is a frequent type of ADNSHL.

Dado el actual potencial de las aplicaciones de la nanotecnología en la industria alimentaria, este informe hace referencia al uso de los nanomateriales producidos de forma intencionada en el laboratorio o a nivel industrial y denominados manufacturados (engineered nanomaterials, ENM), que se introducirán deliberadamente en la cadena alimentaria y, por tanto, pueden ser consumidos. Existe una gran variedad de ENM, destacando las nanopartículas, nanofibras, nanoemulsiones y nanoarcillas. En la industria alimentaria se han identificado tres grandes áreas en las que se considera que la nanotecnología puede contribuir de forma beneficiosa: la producción primaria, el procesado y el envasado de alimentos. Debido a su tamaño, los ENM presentan a menudo propiedades físicas y químicas únicas, las cuales difieren significativamente de las correspondientes al mismo material a mayor escala, lo que implica que no es posible inferir su toxicocinética y perfil de toxicidad por extrapolación a partir de datos de sus equivalentes no nanoestructurados. Estos estudios son imprescindibles para una correcta evaluación del riesgo, la cual se puede realizar mediante el modelo convencional, pero teniendo en cuenta las propiedades específicas de los ENM. Son muchas las limitaciones existentes para completar el proceso, destacando la necesidad de disponer de información sobre la caracterización de los ENM, la bioacumulación, los posibles efectos tóxicos tras su ingestión u absorción por otras vías, en particular de forma crónica, sus repercusiones a largo plazo en la salud pública, la aplicación de las técnicas analíticas adecuadas para este tipo de materiales, etc. Además, no se dispone de bases de datos con los ENM de uso en la actualidad y de los productos que los contienen. Por todo ello, se considera necesario el profundizar en todos estos aspectos con la finalidad de establecer una legislación específica que proteja al consumidor de los riesgos tóxicos derivados de la exposición a ENM. In view of the current potential for the application of nanotechnology in the food industry, this report refers to the use of nanomaterials deliberately produced in the laboratory or at an industrial level and known as “engineered nanomaterials” (ENM) for their intentional introduction into the food chain and, therefore, potentially consumed. There is already a great variety of ENM, in particular nanoparticles, nanofibres, nanoemulsions and nanoclays. In the food industry, three main areas have been identified as having potential for nanotechnology to make a positive contribution: primary production, processing and food packaging. Due to their size, ENM often present unique physical and chemical properties, significantly different from those corresponding to the same material at a larger scale, implying that it is not possible to infer their toxicokinetics and toxicity profile by extrapolation from data on their non-nanostructured equivalents. These studies are essential for a correct risk assessment, which can be done using the conventional model, but bearing in mind the specific properties of the ENM. There are many limitations on the completion of the process, particularly the need to have information available about the characterization of the ENM, their bioaccumulation, the possible toxic effects after intake or absorption through other routes, in particular chronically, their long-term repercussions on public health, the application of adequate analytical techniques for this kind of material, etc. In addition, there are no databases with information on ENM in current use or the products containing them. For all these reasons, it is considered necessary to go deeper into all these aspects in order to establish specific legislation to protect consumers from the toxic risks derived from exposure to ENM.